Literature DB >> 20878336

Aerosol delivery to ventilated newborn infants: historical challenges and new directions.

Jan Mazela1, Richard A Polin.   

Abstract

There are several aerosolized drugs which have been used in the treatment of neonatal respiratory illnesses, such as bronchodilators, diuretics, and surfactants. Preclinical in vitro and in vivo studies identified a number of variables that affect aerosol efficiency, including particle size, aerosol flows, nebulizer choice, and placement. Nevertheless, an optimized aerosol drug delivery system for mechanically ventilated infants still does not exist. Increasing interest in this form of drug delivery requires more controlled and focused research of drug/device combinations appropriate for the neonatal population. In the present article, we review the research that has been conducted thus far and discuss the next steps in developing the optimal aerosol delivery system for use in mechanically ventilated neonates.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20878336      PMCID: PMC3059826          DOI: 10.1007/s00431-010-1292-6

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  47 in total

Review 1.  Respiratory gas conditioning in infants with an artificial airway.

Authors:  Andreas Schulze
Journal:  Semin Neonatol       Date:  2002-10

2.  Evaluation of pulsed and breath-synchronized nebulization of budesonide as a means of reducing nebulizer wastage of drug.

Authors:  K Nikander; M Turpeinen; P Wollmer
Journal:  Pediatr Pulmonol       Date:  2000-02

Review 3.  Aerosolized surfactants.

Authors:  Jan Mazela; T Allen Merritt; Neil N Finer
Journal:  Curr Opin Pediatr       Date:  2007-04       Impact factor: 2.856

4.  Effect of electrostatic charge, flow, delay and multiple actuations on the in vitro delivery of salbutamol from different small volume spacers for infants.

Authors:  J H Wildhaber; S G Devadason; E Eber; M J Hayden; M L Everard; Q A Summers; P N LeSouëf
Journal:  Thorax       Date:  1996-10       Impact factor: 9.139

5.  Effects of dense, high-volume, artificial surfactant aerosol on a heated exhalation filter system.

Authors:  C F Haas; J G Weg; C W Kettell; E J Caldwell; D S Zaccardelli; D L Brown
Journal:  Crit Care Med       Date:  1993-01       Impact factor: 7.598

6.  Determinants of aerosolized albuterol delivery to mechanically ventilated infants.

Authors:  D M Coleman; H W Kelly; B C McWilliams
Journal:  Chest       Date:  1996-06       Impact factor: 9.410

Review 7.  Special problems in aerosol delivery: artificial airways.

Authors:  R Dhand
Journal:  Respir Care       Date:  2000-06       Impact factor: 2.258

8.  Nebuliser hood compared to mask in wheezy infants: aerosol therapy without tears!

Authors:  I Amirav; I Balanov; M Gorenberg; D Groshar; A S Luder
Journal:  Arch Dis Child       Date:  2003-08       Impact factor: 3.791

9.  The Effects of helium/oxygen mixture (heliox) before and after extubation in long-term mechanically ventilated very low birth weight infants.

Authors:  Claudio Migliori; Paolo Gancia; Elena Garzoli; Vania Spinoni; Gaetano Chirico
Journal:  Pediatrics       Date:  2009-06       Impact factor: 7.124

10.  Airway and body surface sensors for triggering in neonatal ventilation.

Authors:  J John; L J Björklund; N W Svenningsen; B Jonson
Journal:  Acta Paediatr       Date:  1994-09       Impact factor: 2.299

View more
  27 in total

Review 1.  Neonatal non-invasive respiratory support: physiological implications.

Authors:  Thomas H Shaffer; Deepthi Alapati; Jay S Greenspan; Marla R Wolfson
Journal:  Pediatr Pulmonol       Date:  2012-07-06

Review 2.  Challenges Associated with Route of Administration in Neonatal Drug Delivery.

Authors:  Matthew W Linakis; Jessica K Roberts; Anita C Lala; Michael G Spigarelli; Natalie J Medlicott; David M Reith; Robert M Ward; Catherine M T Sherwin
Journal:  Clin Pharmacokinet       Date:  2016-02       Impact factor: 6.447

3.  Generating Charged Pharmaceutical Aerosols Intended to Improve Targeted Drug Delivery in Ventilated Infants.

Authors:  Landon Holbrook; Michael Hindle; P Worth Longest
Journal:  J Aerosol Sci       Date:  2015-10-01       Impact factor: 3.433

4.  In Vitro Assessment of Small Charged Pharmaceutical Aerosols in a Model of a Ventilated Neonate.

Authors:  Landon Holbrook; Michael Hindle; P Worth Longest
Journal:  J Aerosol Sci       Date:  2017-05-13       Impact factor: 3.433

5.  In vitro and in vivo characterization of poractant alfa supplemented with budesonide for safe and effective intratracheal administration.

Authors:  Francesca Ricci; Chiara Catozzi; Francesca Ravanetti; Xabier Murgia; Francesco D'Aló; Natalia Macchidani; Elisa Sgarbi; Valentina Di Lallo; Federica Saccani; Marisa Pertile; Antonio Cacchioli; Silvia Catinella; Gino Villetti; Maurizio Civelli; Francesco Amadei; Fabio Franco Stellari; Barbara Pioselli; Fabrizio Salomone
Journal:  Pediatr Res       Date:  2017-08-23       Impact factor: 3.756

6.  Optimal delivery of aerosols to infants during mechanical ventilation.

Authors:  P Worth Longest; Mandana Azimi; Michael Hindle
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2013-12-03       Impact factor: 2.849

7.  Inhaled Vitamin D: A Novel Strategy to Enhance Neonatal Lung Maturation.

Authors:  Sneha K Taylor; Reiko Sakurai; Tokusho Sakurai; Virender K Rehan
Journal:  Lung       Date:  2016-09-10       Impact factor: 2.584

8.  Development of a new technique for the efficient delivery of aerosolized medications to infants on mechanical ventilation.

Authors:  P Worth Longest; Geng Tian
Journal:  Pharm Res       Date:  2014-08-08       Impact factor: 4.200

Review 9.  Delivery and performance of surfactant replacement therapies to treat pulmonary disorders.

Authors:  Nashwa El-Gendy; Anubhav Kaviratna; Cory Berkland; Prajnaparamita Dhar
Journal:  Ther Deliv       Date:  2013-08

Review 10.  Antenatal hypoxia and pulmonary vascular function and remodeling.

Authors:  Demosthenes G Papamatheakis; Arlin B Blood; Joon H Kim; Sean M Wilson
Journal:  Curr Vasc Pharmacol       Date:  2013-09       Impact factor: 2.719

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.